- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy - Mutation agnostic potential of Actimab-A ...
SAN DIEGO, CA—Rami S. Komrokji, MD, from H. Lee Moffitt Cancer Center & Research Institute in Tampa, FL, and colleagues reported study data indicating that the CLAG regimen (cladribine, cytarabine, ...
A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 ...
(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results